 |
|
|
| |
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies
|
| |
| |
Reported by Jules Levin
Glasgow 2018 Oct 27-31
Alan Oglesby,1Kostas Angelis,2Yogesh Punekar,3Sara Lopes,3Antonio Antela,4Michael Aboud,3Rodicavan Solingen,5Elizabeth Blair,1Lesley Kahl,3Martin Gartland,1Brian Wynne,1Miranda Murray3
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Uxbridge, UK; 3ViiV Healthcare, Brentford, UK; 4Infectious Diseases Unit, Hospital Clinico de Santiago, La Coruna, Spain; 5Janssen PharmaceuticaNV, Beerse, Belgium
|
| |
|
|
|
|
|
